significantly affect their biological activity, as the SEG/Pas-derived Fas/FasL system drives cell apoptosis to a significantly higher extent than the C57BL/6J-system in vitro, and is far more efficient in vivo, subsequently leading to a significant increase in gamma-radiation induced-apoptosis of thymic T cells.
These results lead us to propose that germ-line functional polymorphisms affecting either the levels of expression and/or the biological activity of both Fas and FasL genes could be contributing to the genetic risk to develop T-cell lymphoblastic lymphomas.

**351** POSTER

**Genetic background and cervical development: the influence of cytochromes P450IID6 genotypes**

C. Rodrigues[1], D. Pinto[1], R. Catarino[1], D. Pereira[2], J. Moutinho[3], R. Medeiros[1]. *[1]Portuguese Institute of Oncology, Molecular Oncology Group, Porto, Portugal; [2]Portuguese Institute of Oncology, Medical Oncology Department, Porto, Portugal; [3]Portuguese Institute of Oncology, Gynecology Service, Porto, Portugal*

**Background:** CYP2D6, a member of the Cytochromes P450 (CYP) family, is a phase I metabolic enzyme involved in the oxidative metabolism of numerous endogenous and exogenous molecules, including pro-carcinogens molecules. The CYP2D6*4 polymorphism has been reported to be a major cause of CYP2D6 poor metaboliser phenotype, leading to the absence or decrease in the amount and activity of its protein. The aim of this study was to understand the role of CYP2D6 genotypes on the development of cervical cancer.
**Material and Methods:** This study included 378 patients diagnosed with cervical cancer in the Portuguese Institute of Oncology – Porto, Portugal and 334 women without history of oncology disease. DNA was extracted from peripheral blood and submitted to Polymerase Chain Reaction (PCR) followed by Restriction Fragment Length Polymorphism (RFLP), in order to identify the CYP2D6 genotypes.
**Results:** The genotypes frequencies of the patients group were: 74.30% GG, 21.4% AG and 4.2% AA. In the other group the genotypes frequencies were: 65.57% GG, 27.35% AG and 7.19% AA. We observed that patients carrying the A allele have protection to the development of cervical cancer (OR = 0.698; 95% CI 0.480−1.014; p = 0.059).
**Conclusions:** The A allele of this polymorphism is responsible of the poor metaboliser phenotype. Therefore, women with AG or AA phenotype will have less ability for metabolizing the pro-carcinogenic molecules, which justify the protective association found in this study to the development of cervical cancer. Our results suggests the influence of genetic background as a cofactor in cervical cancer, a human papillomavirus associated neoplasia.

**352** POSTER

**Apicidin overcomes TRAIL-resistance on Bcr-Abl expressing K562 cells through inhibition of PI3K/AKT mediated pathway**

S.J. Park[1], M.J. Kim[1], H.S. Song[2], H.B. Kim[1], C.D. Kang[1], S.H. Kim[1]. *[1]Pusan National University School of Medicine Pusan National University BK21 Medical Science Education Center, Biochemistry, Busan, Korea; [2]Pusan National University School of Medicine, Biochemistry, Busan, Korea*

**Background:** Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic cytokine that is capable of inducing apoptosis in a wide variety of cancer cells but not in normal cells. Although many cancer cells are sensitive to TRAIL-induced apoptosis, Chronic myeloid leukemia (CML) develop resistance to TRAIL. Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer agents, here we investigated histone deacetylase inhibitor apicidin can overcome the TRAIL resistance in CML cells.
**Materials and Methods:** The effect of combination of apicidin with TRAIL in CML-derived K562 cells was assessed by annexin V analysis. Also, activation of caspase and the changes in the amounts of DR4, DR5, PI3K NF-κB, Bcl-xL, and Bcr-Abl proteins were analyzed by immunoblots. The blocking of TRAIL receptor on apicidin-induced sensitization to TRAIL was evaluated as using neutralizing antibodies DR4 and DR5. The effects of inhibiting PI3K and AKT were also examined by treating K562 with LY294002 and AKT inhibitor IV, which are selective inhibitors of PI3K and AKT, respectively. To explore whether expression of Bcr-Abl contributes to TRAIL-resistance, the sensitization of TRAIL on the Bcr-Abl deleted K562 cells was examined.
**Results:** Apicidin enhanced TRAIL-induced apoptosis via caspase activation without mediating through TRAIL receptors, DR4 and DR5, although both receptors are expressed in K562 cells. Apicidin downregulated PI3K and enhanced the effect of LY294002 and AKT inhibitor IV on TRAIL induced-apoptosis. Moreover, Bcr-Abl as well as NF-κB and Bcl-xL were also decreased after treating with apicidin, and Bcr-Abl-deleted K562 cells were sensitized to TRAIL.
**Conclusion:** Our results demonstrated that apicidin can overcome resistance to TRAIL through downregulation of Bcr-Abl and inhibition of PI3K/AKT in K562 cells. Moreover, Inhibition of PI3K activity by apicidin resulted in diminished phosphorylated AKT, inhibition of NF-KB transcriptional activity and significant reduction of expression of NF-KB-dependent protein, Bcl-xL. These were associated with enhancement of the intrinsic sensitivity of cancer cells to cytotoxic effect of TRAIL, therefore, combination of apicidin with TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells

**353** POSTER

**Effect of sulfinosine [(R,S)-2-amino-9-beta-D-ribofuranosylpurine-6-sulfinamide] on lung carcinoma cell lines and its role in overcoming multidrug resistance**

T. Andjelkovic, M. Pesic, J. Bankovic, N. Tanic, S. Ruzdijic. *Institute for Biological Research "Sinisa Stankovic", Department of Neurobiology, Belgrade, Serbia*

The acquired multidrug resistance (MDR) phenotype in cancer cells is defined as resistance to an applied drug, as well as to many structurally and functionally unrelated compounds. It often develops as a result of changes in drug influx/efflux pumps and changes in glutathione (GSH) detoxification system.
Our research was focused on studying the molecular mechanisms underlying MDR in the non-small cell lung carcinoma cell line (NSCLC) that was selected for resistance to doxorubicin (DOX). In an attempt to successfully modulate MDR, we studied the cytotoxicity of sulfinosine (a guanosine analog) on NSCLC cells, its effect on GSH level in cells and potential to alter the expression of MDR-related genes: mdr1, gst-pi and topo II alpha. In addition, we examined the effects of sulfinosine (SF) in combination with an anti-neoplastic agent curcumin.
The cytotoxic effects of SF, curcumin and their combination on sensitive (NCI-H460) and resistant (NCI-H460/R) cell lines was measured by the sulforhodamine B assay, and their interaction was analyzed with Calcusyn software. GSH level in these cells, both treated and untreated, was assessed using Glutathione Colorimetric Detection Kit. The expression of MDR-related genes was evaluated by semi-quantitative RT-PCR.
Our study showed that the cytotoxic effect of SF was dose-dependent in both cell lines. Interaction of SF and curcumin antagonized growth inhibition in the NCI-H460 cell line while their effect on NCI-H460/R was synergistic. In the NCI-H460/R compared to the NCI-H460 cell line, MDR-related genes had significantly altered expression: mdr1 and gst-pi were 7-fold and 50% increased, respectively, whereas topo II alpha was 2-fold decreased. RT-PCR gene expression analysis in the resistant cell line demonstrated that: (i) SF down regulated the expression level of mdr1; (ii) curcumin decreased the expression level of mdr1 and gst-pi; (iii) a combination of these drugs synergistically decreased the expression of mdr1 and not the expression of gst-pi mRNA.
Further studies revealed that GSH level didn't differ between these two cell lines. Still, it was significantly decreased under low concentration of SF both in NCI-H460 and NCI-H460/R.
In general, our results revealed that the MDR phenotype can be modulated by SF and curcumin, both on level of gene expression and on glutathione level. Moreover, the combined application of these two drugs exceeds the effects obtained after treatment of NCI-H460/R with only one agent.

**354** POSTER

**A-toxin enhancement of cisplatin-induced apoptosis in cisplatin-resistant mesothelioma cells**

D. Johansson[1], K. Grankvist[1], A. Johansson[2], R. Henriksson[3], P. Behnam-Motlagh[4]. *[1]Umeå University, Department of Medical Biosciences Clinical Chemistry, Umeå, Sweden; [2]Umeå University, Department of Odontology Oral Cell Biology, Umeå, Sweden; [3]Umeå University, Department of Radiation Sciences Oncology, Umeå, Sweden; [4]Umeå University, Department of Medical Biosciences Clinical Chemistry and Department of Radiation Sciences Oncology, Umeå, Sweden*

Cisplatin (cis-diamminedichloroplatinum) is a drug used in the treatment of several solid tumors and is extensively used in the treatment of pulmonary mesothelioma. After an initial response the effectiveness of cisplatin is often hampered by inherent or acquired cisplatin resistance causing a severe problem in the treatment of these malignancies. α-toxin (α-hemolysin) from Staphylococcus aureus is a pore-forming toxin which induces apoptosis (intrinsic cell suicide) in eukaryotic cells. Disability to enter apoptosis is a key component in the development of cancer. Finding methods to overcome tumour cell drug resistance to apoptosis could greatly enhance current chemotherapy.